Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Securetech Innovations Partnership with QStak Holding, LLC Worth $26.5M
SecureTech Innovations entered into a strategic partnership with QStak Holding involving an exclusive worldwide license for blockchain technology, the formation of a majority-owned joint venture (QStak Market, LLC), and the acquisition of a 15% equity stake in QStak. The total transaction value includes up to $22 million in Series B Preferred Stock for the license and $4.5 million in Series A Preferred Stock for the equity investment.
GrabAGun Digital Holdings Signs $34M M&A Deal with Camfour Holding, Inc.
GrabAGun Digital Holdings Inc. completed the acquisition of Camfour LLC, a national wholesale distributor of firearms and ammunition, for approximately $34.0 million in cash. The deal integrates Camfour's distribution infrastructure with GrabAGun's AI-driven technology platform to expand its reach into wholesale distribution and improve inventory productivity.
Bread Financial Holdings launched an underwritten public offering of depositary shares, each representing a 1/40th interest in its Series C Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock. The company intends to use the net proceeds for general corporate purposes, including potential capital contributions to its subsidiary, Comenity Capital Bank, and share repurchases.
60 Degrees Pharmaceuticals announced positive clinical and molecular results from the first five patients in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. All five patients (100%) reported significant clinical improvement and tested negative for Babesia on conventional PCR tests, supporting the potential efficacy of the combination therapy in immunosuppressed patients.
Guidewire Software Signs $1.7B M&A Deal with Hyperexponential Ltd
Guidewire Software has entered into a definitive agreement to acquire Hyperexponential Ltd, a London-based provider of AI-native underwriting and pricing software, for a base purchase price of $1.7 billion in cash. The deal includes up to $400 million in additional contingent consideration based on recurring revenue targets and is expected to close in the second quarter of fiscal year 2027. To fund the acquisition, Guidewire secured a $1.0 billion senior secured incremental term loan commitment from Bank of America and Citibank.
Value
$1.7B
Counterparty
Hyperexponential Ltd
“Insurance is a distinctly complex industry, where the quality of risk decisions has an immense impact on business outcomes. Guidewire and hyperexponential are uniquely positioned to deliver industry-specific AI solutions that will transform commercial underwriting. Together we will bring greater and more scalable intelligence to the insurance decisions that will help underwrite the risks of tomorrow.”
Mike Rosenbaum, chief executive officer, Guidewire
“Guidewire is the most trusted name in P&C insurance technology, with deep expertise in managing and safeguarding the policy and risk information insurers rely on throughout the insurance lifecycle. Together, we’ll bring insight from submission to bind and from the individual risk to the entire portfolio. With hx and Guidewire, insurers will be able to respond to submissions faster and, more importantly, improve loss ratios and allocate capital more effectively.”
Amrit Santhirasenan, CEO and co-founder, hyperexponential
MidCap Financial Investment Signs $2.6B M&A Deal with Ares Capital Corporation
MidCap Financial Investment Corporation (MFIC) has entered into a definitive agreement to be acquired by Ares Capital Corporation (ARCC) in a stock-and-cash transaction with a total enterprise value of approximately $2.6 billion. MFIC stockholders are expected to receive $10.88 per share, representing a 30.1% premium to the last closing price, consisting of $1.21 in cash and the remainder in ARCC common stock. The merger will consolidate MFIC into ARCC, strengthening ARCC's position as the largest publicly traded business development company.
Vertiv Holdings Signs $1.45B M&A Deal with Utility Innovation Holdings, Inc.
Vertiv Holdings Co completed the acquisition of Utility Innovation Holdings, Inc. (UIG) for $1.45 billion in upfront cash plus up to $1.15 billion in potential earnout payments. UIG provides microgrid solutions and advanced power controls, extending Vertiv's capabilities upstream to the grid interconnect to help data center operators manage power constraints for AI infrastructure.
Value
$1.45B
Counterparty
Utility Innovation Holdings, Inc.
“As AI data center operators work to accelerate deployment in an increasingly power-constrained environment, access to power has become a critical competitive advantage. With UIG now part of Vertiv, we can extend our capabilities upstream to the utility interconnect and onsite power sources, creating a coordinated solution, from behind-the-meter power generation to chip, that helps customers achieve faster time to power without tying them to a single generation technology or supplier.”
Giordano Albertazzi, Vertiv CEO
“UIG is excited to advance its mission to solve the power constraints that are slowing AI data center development. As part of Vertiv, we will be able to bring our microgrid and behind-the-meter power expertise to a broader set of customers globally, helping accelerate deployment of the critical infrastructure needed to support the growth of AI.”
Ares Capital Signs $2.6B M&A Deal with MidCap Financial Investment Corporation
Ares Capital Corporation (ARCC) has entered into a definitive agreement to acquire MidCap Financial Investment Corporation (MFIC) for a total enterprise value of approximately $2.6 billion. MFIC stockholders will receive $10.88 per share in a stock-and-cash transaction, representing a 30.1% premium to MFIC's last closing price. The deal strengthens ARCC's position as the largest publicly traded business development company (BDC) in the U.S.
Aclaris Therapeutics announced positive Phase 1b proof-of-concept results for ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with atopic dermatitis and asthma. The data showed a 45% placebo-adjusted mean improvement in EASI scores for atopic dermatitis and rapid improvements in lung function for asthma patients, with a favorable safety profile and no observed conjunctivitis. The company plans to prioritize Phase 2b development of ATI-052 for eosinophilic esophagitis (EoE) starting in early 2027.
Valion Bio, Inc. entered into side letters to issue Series B and Series C Preferred Shares and warrants for total proceeds of approximately $4.77 million. The transaction includes a $50,000 Series B closing with 3i, LP and a $4.72 million Series C closing with existing purchasers, part of which satisfies overdue cash true-up obligations.
Perpetua Resources entered into an Ordnance Technology Initiative Agreement with the U.S. Army to fund a program evaluating tungsten production at the Stibnite Mining District. The $85 million cost-share program includes a $40 million equity-like investment from the U.S. Army to support drilling, metallurgical testing, and engineering through 2029.
North Haven Private Income Fund Capital Raise of $1.89M
North Haven Private Income Fund LLC sold approximately 106,999 Class S units for aggregate proceeds of $1.89 million in a private placement. The Fund also declared a monthly distribution of $0.1185 per unit and reported an estimated Net Asset Value of $2,946.8 million as of September 30, 2026.
FF EAI Robotics Ecosystem M&A Deal with Faraday Future Intelligent Electric Inc.
FF EAI Robotics Ecosystem Inc. (FFR) announced the completion of its acquisition of the robotics business and related assets from Faraday Future Intelligent Electric Inc. (FFAI). As consideration, FFR issued common and non-voting convertible preferred shares to a subsidiary of FFAI, transforming FFR into a pure-play humanoid and bionic Physical AI robotics company.
Faraday Future Intelligent Electric Divestiture to FF EAI Robotics Ecosystem Inc.
Faraday Future Intelligent Electric Inc. (FFAI) completed the disposition of its robotics business and related assets to FF EAI Robotics Ecosystem Inc. (FFR) on October 23, 2026. In exchange for the assets, FFR issued common and non-voting convertible preferred shares to FFAI's subsidiary, Smart Technology Holdings Ltd. Following the transaction, FFR operates as a pure-play humanoid and bionic robotics company while FFAI remains a shareholder.
The New York Stock Exchange (NYSE) has commenced proceedings to delist Eve Holding's public warrants (EVEXW) and immediately suspended their trading due to abnormally low selling price levels. The company's common stock (EVEX) is unaffected by this action and will continue to trade on the NYSE.
Luxfer Holdings M&A Deal with Double Eagle Acquisition Buyer, Inc.
Luxfer Holdings PLC provided a status update regarding its pending acquisition by Double Eagle Acquisition Buyer, Inc., an entity owned by Wynnchurch Capital. The company is issuing supplemental proxy disclosures to address two shareholder lawsuits and several demand letters alleging disclosure deficiencies in the definitive proxy statement. The shareholder meetings to vote on the transaction remain scheduled for November 4, 2026.
Venu Holding Corp entered into a series of agreements for the continued development and financing of 'The Sunset McKinney,' a major open-air amphitheater and entertainment complex in Texas. The transaction includes an amended development agreement with the City of McKinney and a sale-leaseback arrangement with STORE Capital involving the 46-acre project site. The project was previously supported by a $35 million land acquisition involving a $25 million promissory note to the McKinney Economic Development Corporation.
Equillium triggered a $20 million milestone closing of a previously announced private placement following the dosing of the first patient in its Phase 1 clinical trial of EQ504. The company is issuing approximately 14.9 million shares and 20.1 million pre-funded warrants to institutional and accredited investors. The proceeds are expected to extend the company's cash runway into 2029.
Sculptor Diversified Real Estate Income Trust Capital Raise
Sculptor Diversified Real Estate Income Trust announced its intention to conduct a private offering of two new share classes, Class II and Class SII common stock. In connection with the offering, the company increased its authorized capital stock to 2.6 billion shares and amended its advisory and operating partnership agreements to reflect the new share structure.
Apollo Infrastructure Company LLC issued and sold unregistered shares across multiple series to third-party investors for approximately $39.5 million in cash. The company also updated its Transactional Net Asset Value (NAV) per share as of September 30, 2026, and announced its intention to conduct quarterly share repurchases for up to 5.0% of its aggregate NAV.
DataMeds AI M&A Deal with EOS Technology Holdings, Inc.
DataMEDS AI entered into a second amended and restated non-binding letter of intent to acquire intellectual property assets from EOS and Scilex Holding Company, and a controlling interest in Tollo Health (d/b/a Health Lives Here). The transaction involves an exchange of membership interests and the issuance of common stock that will result in the counterparties owning approximately 89.5% of the company's common stock on a fully diluted basis.
YHN Acquisition I Limited received a Staff Determination notice from Nasdaq on October 21, 2026, stating that the company failed to regain compliance with minimum market value requirements for continued listing. The company's board has decided not to appeal the delisting or transfer to the Nasdaq Capital Market, and trading is expected to be suspended on October 30, 2026. The company intends to apply for quotation on the OTC Markets following the delisting.
Zeo Energy Corp. received a 180-day extension from Nasdaq, until April 19, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company's Class A common stock will continue to trade on the Nasdaq Capital Market during this period while management monitors the stock price and considers options to meet the listing standard.
Lycia Therapeutics, Inc. filed its Amended and Restated Certificate of Incorporation and Bylaws in connection with the closing of its initial public offering. These governance changes were previously approved by the board and stockholders to take effect upon the IPO's completion.
Rallybio Signs $82.7M M&A Deal with Avenzo Therapeutics, Inc.
Rallybio Corporation provided a status update on its pending merger with Avenzo Therapeutics, declaring a special cash distribution of approximately $82.7 million ($13.56 per share) to stockholders. The distribution is based on the company's estimated net cash exceeding zero prior to the merger closing and is scheduled for payment on November 13, 2026.
Apollo Asset Backed Credit Co Capital Raise of $34.7M
Apollo Asset Backed Credit Company LLC issued and sold unregistered shares across multiple classes for total aggregate consideration of approximately $34.73 million as of October 1, 2026. The company also disclosed its Transactional Net Asset Value (NAV) per share as of September 30, 2026, which serves as the pricing basis for ongoing sales and its quarterly share repurchase program.
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.
Longeveron announced updated Phase 2b ELPIS II trial results for laromestrocel in infants with hypoplastic left heart syndrome (HLHS). While the trial missed its primary efficacy endpoint of RVEF change, additional analysis showed the secondary endpoint of major adverse cardiac events (MACE) achieved statistical significance with only 1 event in the treatment arm versus 8 in the standard of care arm (P=0.043).
Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The submission is supported by Phase 2 FIGHT DMD trial data showing a statistically significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. While the FDA expressed concerns regarding the sufficiency of the data package for efficacy requirements, the company is moving forward with the submission following a pre-NDA meeting.
Weave Communications Signs $650M M&A Deal with Francisco Partners
Weave Communications, Inc. completed its acquisition by Francisco Partners in an all-cash transaction valued at approximately $650 million. Under the terms of the deal, Weave stockholders received $7.40 per share, and the company has transitioned to a privately held entity, delisting from the New York Stock Exchange.
Value
$650M
Counterparty
Francisco Partners
“Today marks the start of an exciting new chapter for Weave. For nearly two decades, Weave has built solutions for independent practices caring for patients in communities across the country. Today, more than 40,000 locations rely on us to deepen their relationship with patients through automated communication and engagement solutions. With Francisco Partners’ support and resources, we’re well positioned to deliver even more value to the practices we serve. I want to thank our employees, whose dedication made this milestone possible.”
Brett White, Chief Executive Officer of Weave
“Weave sits at the center of how tens of thousands of healthcare practices communicate with their patients and collect revenue. We are pleased to officially partner with Brett and the Weave team and see significant opportunity to build on that position through continued product innovation in AI-powered patient engagement and payments solutions.”